Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Greenblatt M, Debnath S, Yallowitz A, McCormick J, Lalani S, Zhang T, et al. Identification of a stem cell mediating osteoblast versus adipocyte lineage selection. Res Sq. 2023.

Girardi NI, Cushing MM. Pick Your Poison: Anemia or Transfusion. Ann Thorac Surg. 2023;116(5):1119.

Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, et al. BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Science. 2023;379(6629):eabj7412.

Martinez-Ordoñez A, Duran A, Ruiz-Martinez M, Cid-Diaz T, Zhang X, Han Q, et al. Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. Cancer Cell. 2023;41(2):252-271.e9.

Yang HS, Wang F, Greenblatt MB, Huang SX, Zhang Y. AI Chatbots in Clinical Laboratory Medicine: Foundations and Trends. Clin Chem. 2023;69(11):1238-1246.

Potter RF, Zhang K, Reimler B, Marino J, Muenks CE, Alvarado K, et al. Uncharacterized and lineage-specific accessory genes within the Proteus mirabilis pan-genome landscape. mSystems. 2023;8(4):e0015923.

Limberg J, Lee-Saxton YJ, Egan CE, AlAnazi AA, Easthausen I, Stefanova D, et al. Perineural Invasion in Papillary Thyroid Cancer: A Rare Indicator of Aggressive Disease. Ann Surg Oncol. 2023;30(6):3570-3577.

Marx CE, Schenker C, Xu Y, Salvatore SP, Kahn SR, Garcia D, et al. Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort. J Thromb Haemost. 2023;21(10):2908-2912.

Elhadad S, Redmond D, Tan A, Huang J, Rodriguez BL, Racine-Brzostek SE, et al. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023;225:47-56.

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.